ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

 
Print Page
Email Article

Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology

  [ 46 votes ]   [ Discuss This Article ]
www.ProHealth.com • September 23, 2003


Company to develop therapies centering on the nervous system's role in controlling systemic inflammatory responses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 2, 2003-- Critical Therapeutics, Inc. (CTI) today announced the issuance of a U.S. patent covering therapies designed to control destructive inflammatory processes by regulating a key reflex pathway between the central nervous system and the major organs.

U.S. Patent No. 6,610,713, entitled "Inhibition of Inflammatory Cytokine Production by Cholinergic Agonists and Vagus Nerve Stimulation," covers methods of treating a broad range of serious inflammatory diseases. The invention described in the patent embodies novel approaches to inhibit the cellular release of pro-inflammatory cytokines through administration of cholinergic receptor agonists or direct stimulation, including electrical stimulation of the vagus nerve. The vagus nerve is a major signaling pathway for the anti-inflammatory signal between the brain and major organs such as the heart, stomach, liver and small intestine.

For decades, researchers thought the vagus nerve was involved chiefly in the process of regulating the function of internal organs. In recent years, however, scientists have discovered that the vagus nerve plays a vital role in regulating the immune system. Specifically, vagus nerve stimulation has been shown to release a substance known as acetylcholine, which in turn inhibits the production by macrophages of pro-inflammatory, potentially lethal proteins called cytokines. It is the immune system's overproduction of these cytokines, including tumor necrosis factor (TNF), that can contribute to illnesses such as rheumatoid arthritis, Crohn's disease, ulcerative colitis and sepsis.

Patent No. 6,610,713 stems from research conducted by the inventor - CTI co-founder Kevin J. Tracey, M.D. - and his colleagues at North Shore-Long Island Jewish Research Institute's Laboratory of Biomedical Research. CTI in-licensed exclusive rights to the patent from the Institute. In an article published in the December 22, 2002 online edition of Nature, Dr. Tracey and his team identified the essential chemical receptor that dispatches a signal that inhibits the production of TNF. That receptor, which contains the nicotinic a-7 cholinergic receptor subunit, is necessary to inhibit the release of TNF and other pro-inflammatory cytokines.

"Dr. Tracey's research underscores the potential of pharmacological and electrical stimulation therapies that target a -7 subunits on peripheral immune cells," said Walter Newman, Ph.D., CTI's Chief Scientific Officer. "The issuance of this patent enables us to leverage our worldwide exclusive license to develop treatment methods based one or more approaches."

Source: www.eurekalert.org



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Optimized Curcumin Longvida® Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Enhance Eyelashes Naturally Enhance Eyelashes Naturally
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map